Sometimes, cancer patients receive an initial treatment, followed by additional treatment to
lower the chance of cancer coming back. The standard or usual treatment for this type of
disease is initially having radiation therapy at the same time as chemotherapy (with a drug
called cisplatin), with no additional therapy afterwards
This study is looking at whether a type of drug called durvalumab can be used with radiation
during the initial treatment, (instead of cisplatin) and also afterwards as additional
therapy. Durvalumab is an immunotherapy drug . It has been tested in many different types of
cancers. Durvalumab works by allowing the immune system to detect the cancer and reactivate
the immune response. This may help to slow down the growth of cancer or may cause cancer
cells to die. Durvalumab has been shown to shrink tumours in animals. It has been studied in
more than 5000 people, approved for use in other cancers and seems promising.
This clinical trial will also test another type of immunotherapy drug called tremelimumab,
which would also be given as additional treatment. Tremelimumab works in a different way to
durvalumab to enhance the immune system reaction against cancer cells and may improve the
effect of durvalumab. Tremelimumab may also help slow the growth of the cancer cells or may
cause cancer cells to die. It has been shown to shrink tumours in animals. Tremelimumab has
been studied in over 1200 people, approved for use in other cancers and seems promising.
As of February 2019, tremelimumab will no longer be tested with new participants joining the
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.